Search Results

Suggestions that the U.S. should emulate other countries on drug price controls or patents obscure how our present policies have allowed drug development to flourish.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.

A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the CJS Securities 24th Annual New Ideas Summer Conference on Wednesday, July 10, 2024, in White Plains, New York.

The American Academy of Orthopaedic Surgeons announced a call for proposals for the AAOS IDEA Grant Program®, a multi-year initiative to inspire diversity, equity and access across the field of orthopaedics.

An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.

Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024.